



Pioneering science delivers vital medicines™

**Amgen Mission**

To serve patients

**Amgen Quick Facts**

**Headquarters**

Thousand Oaks, California

**Staff**

Approximately 17,000 worldwide

**Stock Listing**

NASDAQ: AMGN

**Chairman and CEO**

Kevin W. Sharer

**2011 Financial Highlights**

Total revenue: \$15.6 billion

Product sales: \$15.3 billion

R&D expense: \$3.2 billion

**Address/Phone**

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

Main: (805) 447-1000

Investors: (805) 447-1060

**Principal Products**

Aranesp® (darbepoetin alfa)

Enbrel® (etanercept)

EPOGEN® (Epoetin alfa)

Neulasta® (pegfilgrastim)

NEUPOGEN® (Filgrastim)

Nplate® (romiplostim)

Prolia® (denosumab)

Sensipar® (cinacalcet)

Vectibix® (panitumumab)

XGEVA® (denosumab)

For product information, including important safety information, visit [www.amgen.com](http://www.amgen.com).

**About Amgen**

Amgen discovers, develops, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing novel medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen is committed to advancing science to dramatically improve people’s lives.

**Reaching Patients Worldwide**

Amgen medicines help patients around the world. The company has facilities or subsidiaries in the following locations:

**United States (including Puerto Rico)**

California (South San Francisco, Thousand Oaks)

Colorado (Boulder, Longmont)

Kentucky (Louisville)

Massachusetts (Cambridge, Woburn)

Puerto Rico (Juncos)

Rhode Island (West Greenwich)

Washington (Bothell, Seattle)

Washington, D.C.

**Outside the United States**

Australia

Finland

Latvia

Russia

Austria

France

Lithuania

Slovakia

Belgium

Germany

Luxembourg

Slovenia

Brazil

Greece

Mexico

Spain

Bulgaria

Hong Kong

New Zealand

Sweden

Canada

Hungary

The Netherlands

Switzerland

China

India

Norway

Turkey

Czech Republic

Ireland

Poland

United Arab Emirates

Denmark

Italy

Portugal

United Kingdom

Estonia

Japan

Romania

## Leadership Team

### Kevin W. Sharer

Chairman of the Board and  
Chief Executive Officer

### Robert A. Bradway

President and Chief Operating Officer

### David W. Beier

Senior Vice President,  
Global Government Affairs,  
Communications and Philanthropy

### Fabrizio Bonanni

Executive Vice President,  
Operations

### Sean Harper

Senior Vice President,  
Global Development and  
Corporate Chief Medical Officer

### Rolf Hoffmann

Senior Vice President,  
International Commercial Operations

### Anthony Hooper

Executive Vice President,  
Global Commercial Operations

### Diana McKenzie

Senior Vice President and  
Chief Information Officer

### Brian M. McNamee

Senior Vice President,  
Human Resources

### Joshua J. Ofman

Senior Vice President,  
Global Value and Access

### Jonathan M. Peacock

Executive Vice President and  
Chief Financial Officer

### Roger M. Perlmutter

Executive Vice President,  
Research and Development

### Anna Richo

Senior Vice President and  
Chief Compliance Officer

### David J. Scott

Senior Vice President,  
General Counsel and Secretary

## *An Interdisciplinary Approach to R&D*

For more than 30 years, Amgen has been a leading innovator in the identification, isolation, production, and use of human proteins as therapeutic agents. We focus on pioneering treatments for serious illness. Our R&D organization has cultivated expertise in multiple treatment modalities—large-molecule proteins, small molecules, and antibodies—allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target. Our R&D facilities are located in South San Francisco and Thousand Oaks, California; Cambridge and Woburn, Massachusetts; Seattle, Washington; Burnaby, British Columbia, Canada; Abingdon, Cambridge, and Uxbridge, UK; Regensburg, Germany; and clinical development offices in additional locations around the world.

## *A Pioneer in Biotechnology Manufacturing*

Assuring that Amgen medicines rapidly, reliably, and safely reach patients is the charge of Amgen's manufacturing, process development, quality, and distribution teams. Manufacturing therapies based on proteins found in the human body is a complex and highly specialized activity. From process development and clinical manufacturing to full-scale therapeutic protein production, Amgen has built one of the industry's largest and most reliable operations. Amgen operates manufacturing facilities in California, Colorado, Rhode Island, Washington, and Puerto Rico.

## *Advancing Science through Strategic Partnerships*

With more than 100 active collaborations, Amgen is well-suited to be a partner of choice in the human therapeutics business. With the capabilities and financial strength of a large company, Amgen can offer partners the resources to support a potential new medicine as it advances from lab to clinic to marketplace. At the same time, Amgen retains the agility and decisiveness of a smaller biotech, with an unwavering commitment to science and patients.

## *Philanthropy that Makes a Positive Difference*

The causes Amgen supports, through the Amgen Foundation and other channels, reflect the company's efforts to elevate science, help patients, and improve lives.

### The Amgen Foundation

The Amgen Foundation ([www.amgen.com/citizenship/overview.html](http://www.amgen.com/citizenship/overview.html)) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made more than \$160 million in grants to local, regional, and national nonprofit organizations that impact society in inspiring and innovative ways. It has also supported disaster relief efforts both domestically and internationally.

### Science Education

Amgen is inspiring and preparing the scientists of tomorrow through several signature science education programs, including Amgen Scholars, an eight-year, \$34 million program for undergraduates; the Teach For America Amgen Fellows Program; the Amgen Bruce Wallace Biotechnology Lab Program; and the Amgen Award for Science Teaching Excellence.

### Community Involvement

In the communities in which Amgen staff live and work, the company commits millions of dollars in charitable donations, and staff members devote thousands of hours of personal time, to programs and services that can make meaningful differences in people's lives.

## Investor Information

This fact sheet is a summary of more detailed disclosure that can be found in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on [www.amgen.com/investors](http://www.amgen.com/investors). The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.

